Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | RNA binding protein | 0.0076 | 0.4963 | 0.4963 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 0.2503 | 0.5043 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.4963 | 0.4963 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 0.2503 | 0.5043 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.338 | 0.338 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.4963 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.2503 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.2503 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.4963 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.338 | 0.6812 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.2503 | 0.5 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.338 | 0.338 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 0.4963 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.4963 | 0.4963 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.4963 | 1 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 1 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.4963 | 0.4963 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.338 | 0.6812 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.4963 | 0.4963 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.338 | 0.6812 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.4963 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.4963 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.338 | 0.6812 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.338 | 0.6812 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.338 | 0.6812 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.2503 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 0.2503 | 0.5043 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.4963 | 0.4963 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 0.2503 | 0.5043 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.338 | 0.6812 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 0.4963 | 1 |
Brugia malayi | hypothetical protein | 0.0043 | 0.2503 | 0.2503 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 2.3109 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 5.6234 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 5.8584 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 10 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.